
Insight Molecular Diagnostics Inc.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
Company Overview
A concise company profile alongside the latest public filing activity.
Insight Molecular Diagnostics develops molecular diagnostic tests, including liquid biopsy technology used to detect and monitor cancer through blood-based biomarkers rather than traditional tissue biopsies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P.10% Owner | Buy | $6.00M | 3,428,571at $1.75 | Nov 17, 2026 |
| BROADWOOD PARTNERS, L.P.10% Owner | Buy | $0 | 0Price not reported | Nov 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable IMDX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.